• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

t(4;14)、del(17p13)、del(1p32)和1q21获得性荧光原位杂交探针的联合使用可识别克隆异质性,并提高233例新诊断多发性骨髓瘤中不良细胞遗传学特征的检测率。

Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma.

作者信息

Smol Thomas, Dufour Annika, Tricot Sabine, Wemeau Mathieu, Stalnikiewicz Laure, Bernardi Franck, Terré Christine, Ducourneau Benoît, Bisiau Hervé, Daudignon Agnès

机构信息

Service d'Hématologie-Immunologie-Cytogénétique, CH Valenciennes, Valenciennes, France.

Université de Lille Nord de France, Lille, France.

出版信息

Mol Cytogenet. 2017 Jul 1;10:26. doi: 10.1186/s13039-017-0327-3. eCollection 2017.

DOI:10.1186/s13039-017-0327-3
PMID:28680482
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5493886/
Abstract

BACKGROUND

Our aim was to set the FISH combination of del(17p13), t(4;14), 1q21 gain and del(1p32), four adverse cytogenetic factors rarely evaluated together, and compare our technical thresholds with those defined in the literature.

METHODS

Two hundred thirty-three patients with MM at diagnosis were studied using FISH to target 4 unfavorable cytogenetic abnormalities: 17p13 deletion, t(4;14) translocation, 1p32 deletion and 1q21 gain. Technical thresholds were determined for each probe using isolated CD138-expressing PC from patients without MM.

RESULTS

The FISH analysis identified abnormalities in 79.0% of patients. Del(17p13) was detected in 15.0% of cases, t(4;14) in 11.5%, 1q21 gain in 37.8% and del(1p32) in 8.7%. Adding 1p32/1q21 FISH probes has enabled us to identify adverse cytogenetic profiles in 39.0% of patients without del(17p13) or t(4;14). Clonal heterogeneity was observed in 51.1% of patients as well as an increase in the number of adverse abnormalities when related clones were greater than or equal to 2 (85.1% against 45.6%).

CONCLUSION

FISH allowed detecting accumulation of adverse abnormalities and clonal heterogeneity in MM with a combination of 4 probes. The impacts of these two parameters need to be evaluated, and could be included in future cytogenetic classifications.

摘要

背景

我们的目的是确定del(17p13)、t(4;14)、1q21增益和del(1p32)这四种很少一起评估的不良细胞遗传学因素的荧光原位杂交(FISH)组合,并将我们的技术阈值与文献中定义的阈值进行比较。

方法

对233例初诊的多发性骨髓瘤(MM)患者进行研究,使用FISH检测4种不良细胞遗传学异常:17p13缺失、t(4;14)易位、1p32缺失和1q21增益。使用来自非MM患者的分离的表达CD138的浆细胞(PC)为每个探针确定技术阈值。

结果

FISH分析在79.0%的患者中发现了异常。15.0%的病例检测到del(17p13),11.5%检测到t(4;14),37.8%检测到1q21增益,8.7%检测到del(1p32)。添加1p32/1q21 FISH探针使我们能够在39.0%没有del(17p13)或t(4;14)的患者中识别出不良细胞遗传学特征。51.1%的患者观察到克隆异质性,当相关克隆数大于或等于2时,不良异常数量增加(85.1%对45.6%)。

结论

FISH使用4种探针的组合能够检测MM中不良异常的积累和克隆异质性。这两个参数的影响需要评估,并可纳入未来的细胞遗传学分类中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/209d/5493886/b17d51f866ff/13039_2017_327_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/209d/5493886/3a5fd66666a5/13039_2017_327_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/209d/5493886/b17d51f866ff/13039_2017_327_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/209d/5493886/3a5fd66666a5/13039_2017_327_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/209d/5493886/b17d51f866ff/13039_2017_327_Fig2_HTML.jpg

相似文献

1
Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma.t(4;14)、del(17p13)、del(1p32)和1q21获得性荧光原位杂交探针的联合使用可识别克隆异质性,并提高233例新诊断多发性骨髓瘤中不良细胞遗传学特征的检测率。
Mol Cytogenet. 2017 Jul 1;10:26. doi: 10.1186/s13039-017-0327-3. eCollection 2017.
2
Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.通过荧光原位杂交技术检测初诊多发性骨髓瘤患者 1p32.3 缺失的临床特征及预后价值:中国单中心研究。
Front Med. 2020 Jun;14(3):327-334. doi: 10.1007/s11684-019-0712-x. Epub 2019 Nov 29.
3
p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain).p53-NEIL1 共异常诱导基因组不稳定性,并与同时存在 17p13(del) 和 1q21(gain) 的多发性骨髓瘤中的 Chk1 抑制协同导致合成致死。
Oncogene. 2022 Apr;41(14):2106-2121. doi: 10.1038/s41388-022-02227-8. Epub 2022 Feb 21.
4
[The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].[Del(1p32)在新诊断多发性骨髓瘤患者中的预后价值]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):768-773. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.017.
5
[Cytoplasmic light-chain immunofluorescence combined with FISH in bone marrow smears to detect cytogenetic abnormalities in multiple myeloma].[骨髓涂片细胞质轻链免疫荧光联合荧光原位杂交检测多发性骨髓瘤细胞遗传学异常]
Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):566-570. doi: 10.3760/cma.j.cn121090-20231204-00291.
6
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.1p32 双等位基因缺失定义为超高危骨髓瘤,但单等位基因 del(1p32) 仍然是一个强有力的预后因素。
Blood. 2023 Mar 16;141(11):1308-1315. doi: 10.1182/blood.2022017863.
7
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. 多发性骨髓瘤患者 1q21 扩增伴额外遗传学异常显著恶化不良预后。
Hematol Oncol. 2013 Mar;31(1):41-8. doi: 10.1002/hon.2018. Epub 2012 Jun 6.
8
Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.多重连接依赖探针扩增和荧光原位杂交是检测多发性骨髓瘤细胞遗传学异常的互补技术。
Genes Chromosomes Cancer. 2013 Sep;52(9):785-93. doi: 10.1002/gcc.22074. Epub 2013 May 30.
9
[Application Value of CD138 MACS-FISH in the Genetic Diagnosis of Plasma Cell Dyscrasia].CD138磁珠分选荧光原位杂交技术在浆细胞肿瘤基因诊断中的应用价值
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Oct;24(5):1437-1442. doi: 10.7534/j.issn.1009-2137.2016.05.028.
10
Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.采用间期荧光原位杂交技术研究多发性骨髓瘤患者的分子细胞遗传学畸变。
Exp Oncol. 2007 Jun;29(2):116-20.

引用本文的文献

1
abnormalities identified by fluorescence hybridization during follow-up confer poor prognosis in Chinese multiple myeloma.随访期间通过荧光杂交检测到的异常在中国多发性骨髓瘤患者中提示预后不良。
Front Med (Lausanne). 2025 Mar 5;12:1536825. doi: 10.3389/fmed.2025.1536825. eCollection 2025.
2
A predictive risk-scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South-Western China.基于 1q21 增益/扩增的多发性骨髓瘤生存预后预测风险评分模型:中国西南部一家三级医院的经验。
Cancer Med. 2024 Sep;13(17):e70193. doi: 10.1002/cam4.70193.
3
Clinical Relevance of Interferon Regulatory Family-4 (IRF4) Expression in Newly Diagnosed Patients with Multiple Myeloma.

本文引用的文献

1
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.基于基因表达和国际分期系统预测高危和低危多发性骨髓瘤。
Blood. 2015 Oct 22;126(17):1996-2004. doi: 10.1182/blood-2015-05-644039. Epub 2015 Sep 1.
2
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统:国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
3
Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.
干扰素调节因子4(IRF4)表达在新诊断多发性骨髓瘤患者中的临床相关性
Indian J Hematol Blood Transfus. 2023 Oct;39(4):525-536. doi: 10.1007/s12288-023-01628-3. Epub 2023 Jan 16.
4
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).血液系统恶性肿瘤的复杂核型:法语国家血液细胞遗传学组(GFCH)的全面概述。
Leukemia. 2022 Jun;36(6):1451-1466. doi: 10.1038/s41375-022-01561-w. Epub 2022 Apr 16.
5
Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.基于胸腔积液的列线图预测未经选择的多发性骨髓瘤患者的预后:一项大型单中心经验。
Ann Hematol. 2021 Jul;100(7):1789-1801. doi: 10.1007/s00277-021-04484-1. Epub 2021 Mar 14.
6
Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.1q21 获得是接受自体干细胞移植治疗的多发性骨髓瘤患者的不良预后因素:中国多中心研究。
Cancer Med. 2020 Nov;9(21):7819-7829. doi: 10.1002/cam4.3254. Epub 2020 Sep 2.
7
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.多发性骨髓瘤患者细胞遗传学预后指数的建立与验证:对生存的预测作用。
J Clin Oncol. 2019 Jul 1;37(19):1657-1665. doi: 10.1200/JCO.18.00776. Epub 2019 May 15.
8
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.AL 淀粉样变性中单克隆浆细胞异常的细胞遗传学克隆内异质性与多发性骨髓瘤的比较。
Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.
多发性骨髓瘤中高危1q21拷贝数畸变的表观遗传起源证据。
Blood. 2015 Jun 11;125(24):3756-9. doi: 10.1182/blood-2015-03-632075. Epub 2015 May 5.
4
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.蛋白酶体抑制剂和 IMiDs 可克服多发性骨髓瘤中的一些高危细胞遗传学异常,但不能获得 1q21 异常。
Eur J Haematol. 2016 Jan;96(1):46-54. doi: 10.1111/ejh.12546. Epub 2015 Jun 29.
5
The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.克隆大小对多发性骨髓瘤中荧光原位杂交染色体异常预后价值的影响。
Clin Cancer Res. 2015 May 1;21(9):2148-56. doi: 10.1158/1078-0432.CCR-14-2576. Epub 2015 Feb 4.
6
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.额外染色体改变在多发性骨髓瘤中t(4;14)和del(17p)预后价值中的作用:IFM研究经验
Blood. 2015 Mar 26;125(13):2095-100. doi: 10.1182/blood-2014-07-587964. Epub 2015 Jan 30.
7
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.来那度胺联合低剂量地塞米松治疗伴有 17p 缺失和/或(4;14)易位的多发性骨髓瘤:IFM 2010-02 试验结果。
Blood. 2015 Feb 26;125(9):1411-7. doi: 10.1182/blood-2014-11-612069. Epub 2015 Jan 9.
8
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.多发性骨髓瘤:2014 年诊断、风险分层和治疗更新。
Am J Hematol. 2014 Oct;89(10):999-1009. doi: 10.1002/ajh.23810.
9
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.国际评分系统 3 联合高乳酸脱氢酶水平,以及 t(4;14)和/或 del(17p),可识别出接受一线自体造血干细胞移植治疗的多发性骨髓瘤 (MM) 患者,这些患者具有早期 MM 进展相关死亡的高风险。
J Clin Oncol. 2014 Jul 10;32(20):2173-80. doi: 10.1200/JCO.2013.53.0329. Epub 2014 Jun 2.
10
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.染色体 1q21 获得在硼替佐米治疗多发性骨髓瘤中预后不良,但拷贝数变异和受累浆细胞比例无额外预后价值。
Haematologica. 2014 Feb;99(2):353-9. doi: 10.3324/haematol.2013.088211. Epub 2013 Nov 8.